Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - A pilot study

M. Sugiono, M. H. Winkler, A. A. Okeke, M. Benney, D. A. Gillatt

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of bicalutamide vs cyproterone acetate in preventing PSA flare (as a surrogate for tumour flare) for patients requiring luteinizing hormone-releasing hormone (LHRH) analogue therapy for prostate cancer. Patients and methods: In this pilot study, 40 men were randomized 1:1 to bicalutamide 50mg o.d. or cyproterone acetate 100mg t.i.d. 5 days prior to goserelin acetate and continued for 21 days thereafter. PSA, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone were obtained before treatment and on days 6, 8, 10, 16, 21 and 28. Primary end point was PSA. Hormone profile and clinical features including urinary symptoms and bone pain were secondary end points. Results: Both groups were equally matched apart from serum creatinine and ALP. The speed and magnitude of the percentage change in median PSA from baseline was increased for the CPA group but there was no statistically significant difference in the two groups. Although those receiving bicalutamide all showed a testosterone peak, this remained within the normal range. No difference in the frequency of drug-specific adverse events was found. None of the patients died or developed cord compression during the study period. Conclusion: Bicalutamide is able to suppress the initial PSA surge as effectively as cyproterone acetate albeit slightly delayed. A statement whether bicalutamide is equally good at preventing clinical flare cannot be made and should be assessed in an appropriately powered study.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalProstate Cancer and Prostatic Diseases
Volume8
Issue number1
DOIs
Publication statusPublished - Mar 2005
Externally publishedYes

Keywords

  • Bicalutamide
  • Cyproterone acetate
  • Tumour flare

Fingerprint Dive into the research topics of 'Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - A pilot study'. Together they form a unique fingerprint.

  • Cite this